Rare Daily Staff
FDNA said it has launched the Genomics Collaborative, a global initiative involving multiple medical research collaborations using the company’s artificial intelligence and deep learning technologies to develop new precision medicine approaches for diagnosing and treating disease.
In conjunction with the launch, FDNA said it is holding an open call for collaboration with patient advocacy groups, clinicians, labs, and life sciences stakeholders. The company will work with collaborators to design specific studies and capture and analyze patient health data that relates to the proposed research hypotheses.
Projects in the Genomics Collaborative are focused on using computational techniques that integrate phenotypic data into the analysis of human genetics. This process, known as “next-generation phenotyping,” captures, structures and interprets complex physiological information. This next-generation phenotyping data, the company said, can then be used to interpret patient genomic data to help recognize current and future health risks, as well as identify therapeutic targets that will maximize quality and length of life.
FDNA has offered collaborators access to its technologies, which use deep learning neural networks to de-identify and analyze patients’ phenotypic information captured in images, clinical notes, and voice and video recordings to discover correlations between patient data and disease.
Projects already underway at the Genomics Collaborative include one with the Greenwood Genetic Center in Greenwood South Carolina, which seeks to correlate patterns of facial features with metabolite profiles for various genetic syndromes. A second project with Lausanne University Hospital in Switzerland seeks to analyze correlations between bone structure and genomic data in the hopes of improving early diagnosis and intervention for patients with skeletal dysplasia disorders. Bridge the Gap, a Cypress, Texas-based advocacy group, is working with patients, clinicians, and FDNA to study SYNGAP1 gene variants related to Fragile X, Angelman, and other related syndromes to help clinicians provide early diagnosis.
“The Genomics Collaborative is making it possible to look at patients in a safe, secure way to help understand how doctors can better diagnose and treat patients, based on their unique traits,” said Ilana Jacqueline, coordinator of the Genomics Collaborative and manager of patient advocacy for FDNA. “We’re interested in working with others to develop technologies that easily capture and analyze that data to help health care providers have all the facts when they are evaluating patients.”
Advocacy groups, clinicians, and researchers interested in working with the Genomics Collaborative can find more information on its website.
February 28, 2018